Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.

Makiko Suga,Kentaro Fukushima,Tomoaki Ueda,Yasuyuki Arai,Shunsaku Nakagawa,Yosuke Minami,Jun Toda,Akihisa Hino,Jiro Fujita,Takafumi Yokota,Naoki Hosen

Clinical case reports（2022）

引用 1|浏览7

暂无评分

摘要

FMS-like tyrosine kinase 3-internal tandem duplication (-ITD) mutation-positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for -ITD-positive AML-primary induction failure patients with central nervous system involvement.

查看译文

关键词

CNS involvement,FLT3,acute myeloid leukemia,inhibitor,stem cell transplantation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要